home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0341.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
3KB
|
46 lines
Document 0341
DOCN M94A0341
TI A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly
inhibits infectivity of HIV-1 in vitro.
DT 9412
AU Kageyama S; Hoekzema DT; Murakawa Y; Kojima E; Shirasaka T; Kempf DJ;
Norbeck DW; Erickson J; Mitsuya H; Experimental Retrovirology Section,
National Cancer Institute,; Bethesda, Maryland.
SO AIDS Res Hum Retroviruses. 1994 Jun;10(6):735-43. Unique Identifier :
AIDSLINE MED/94355120
AB A C2 symmetry-based HIV protease inhibitor, A77003, exerts potent
antiviral activity against a wide spectrum of HIV isolates in vitro. In
this study, we asked whether A77003 could cause irreversible
conformational changes to HIV-1, whether the amounts of viral RNA and
p24 capsid protein per virion were altered, and how the infectivity of
the virus produced in the presence of the drug was affected. We found
that the number of viral particles and per-virion viral RNA content of
the virus produced in the presence of A77003 did not significantly
differ from those of the virus produced in the absence of the drug,
whereas significant morphological changes were observed as assessed by
transmission electron microscopy. However, the virus produced in the
presence of A77003 contained substantially less p24gag protein per
virion particle as compared to those produced in the absence of the drug
or in the presence of AZT. Virions produced in the presence of A77003
showed up to 50-fold less infectious capability in subsequent tissue
culture than control virions produced in the absence of drug or in the
presence of AZT. This reduction in infectivity was maintained for at
least 10 days in culture. The present data suggest that A77003 impairs
HIV-1 protease-mediated Gag processing, interferes with the assembly and
maturation of the virus, and leads to an irreversible loss of the
infectivity of the virus, although a low but positive level of reversion
to infectivity during the 10-day assay occurs. These features of A77003
(and perhaps similar HIV protease inhibitors as well) anti-HIV activity
should represent desirable properties for antiviral therapy of AIDS and
related diseases.
DE Antiviral Agents/*PHARMACOLOGY Base Sequence Cell Line Comparative
Study Gene Products, gag/ANALYSIS HIV Infections/DRUG
THERAPY/*PREVENTION & CONTROL HIV Protease Inhibitors/*PHARMACOLOGY
HIV-1/*DRUG EFFECTS/PATHOGENICITY/ULTRASTRUCTURE Molecular Sequence
Data RNA, Viral/ANALYSIS Virion/DRUG EFFECTS Zidovudine/PHARMACOLOGY
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).